{"id":"W2003305754","doi":"10.1016/j.ygyno.2008.02.009","title":"Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia","year":2008,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Fallopian tube cancer; Gastrointestinal perforation; Ovarian cancer; Internal medicine; Tolerability; Clinical endpoint; Nausea; Erlotinib; Perforation; Surgery; Vomiting; Gastroenterology; Phases of clinical research; Cancer; Chemotherapy; Adverse effect; Clinical trial; Peritonitis; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003021498,0.001201994,0.001969277,0.0004350048,0.0005510358,0.001333359,0.0007792509,0.001500346,0.003332729],"category_scores_gemma":[0.003014097,0.0006556711,0.001968808,0.0005365351,0.001158582,0.001081788,0.0004974552,0.003798492,0.0005137424],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001269328,"about_ca_system_score_gemma":0.001795367,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002212162,"about_ca_topic_score_gemma":0.005346889,"domain_scores_codex":[0.9991134,0.0005389623,0.0000426335,0.0001408336,0.00007397842,0.00009021192],"domain_scores_gemma":[0.9986665,0.0003789642,0.0003148531,0.00009934058,0.00007565668,0.0004646048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9456588,0.004711685,0.003449609,0.0004444865,0.001764382,0.00002963546,0.0001239387,0.0008164108,0.002168027,0.0002005862,0.003395832,0.03723668],"study_design_scores_gemma":[0.9538072,0.03671461,0.005909408,0.00003898895,0.001126625,0.00004716439,0.00003292747,0.0007100953,0.0003685545,0.0001382386,0.001085327,0.00002092249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868098,0.005706379,0.0003808213,0.001751058,0.0005274001,0.001127878,0.001078393,0.0001007696,0.002517525],"genre_scores_gemma":[0.9894691,0.002132014,0.0008570807,0.001298833,0.0005141133,0.001387929,0.001652022,0.00003368515,0.002655131],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003332729,"threshold_uncertainty_score":0.01597935,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02357263650907375,"score_gpt":0.3040609768563782,"score_spread":0.2804883403473045,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}